Komori
PRISM BioLab (206A) · InitiativeRestatedLatest Earnings presentation (2026-05-18): "Advanced"

AI-Based ADMET Prediction and Candidate Screening Specialized in PepMetics Compounds

First written in FY2024. 3 of 5 entries say "Advanced", first in FY2025-H1. Latest entry: 2026-05-18.

5entries
3years
2from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2024AdvancedFY2025-H1RestatedFY2025Advanced2026-03-12 – 2026-05-182024: 12025: 220252026: 22026
Same theme, other companies
Advancing Drug Discovery Research through AI and InformaticsA theme 13 companies write about · 0 as a headwind · 17 as a tailwind

4 other companies' latest entry also says "Advanced".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  2. FY2025RestatedAnnual report

    「Because our PepMetics technology has characteristics that make it well suited to AI, we are pursuing collaborations to use AI in drug discovery, with the aim of shortening research and development timelines and improving the probability of development success.」

    The use of AI through the business partnership with Elix is continuing.
  3. FY2025-H1AdvancedAnnual report

    「In April, we entered into a joint research agreement with Elix to use AI for compound optimization in the "lead compound discovery" program. Through this partnership, we aim to shorten research and development timelines and improve the probability of development success.」

    A joint research agreement with Elix covering AI-based compound optimization has been signed, and the project has advanced to the stage of utilization through an external partnership.
  4. FY2024First statedAnnual report

    「We are applying rapidly advancing AI (artificial intelligence) technology to PepMetics compounds.」

    We have built and commercialized an ADMET prediction model based on proprietary data and are also using AI to discover candidate compounds.
Moved together

"Progress in the E7386 Phase II Clinical Trial and Clinical POC" moved the same way as this thread, in the same document, in 2 of its 5 moves.

22★12
  1. ★This thread
  2. 1Progress in the E7386 Phase II Clinical Trial and Clinical POC2×
  3. 2Maintaining multiple in-house drug discovery programs and continuously selecting new targets2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for PRISM BioLab yet. It last moved in the Earnings presentation of 2026-05-18: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.